SynthesisAsian Pacific journal of cancer prevention : APJCP2025
GSTP1 rs1695 Variant and Colorectal Cancer Risk in Women Aged 50+: Insights from Iran's Largest Cohort and Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association between GSTP1 rs1695 A>G polymorphism and colorectal cancer (CRC) risk in an Iranian cohort, and to validate findings through a systematic review and meta-analysis.
methodsA multicenter case-control study was conducted in Tehran hospitals, including CRC patients and matched controls. Demographic and clinical data were collected, and DNA was extracted from FFPE tissues and blood. Genotyping of GSTP1 rs1695 was performed using TaqMan® real-time PCR, with 5% of samples validated by direct sequencing. Logistic regression adjusted for age and gender was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), with Bonferroni correction applied. A systematic review and meta-analysis was performed following PRISMA guidelines using five databases, including studies up to January 2025.
resultsThe study included 2,590 participants (1,038 CRC cases). CRC incidence was higher in individuals aged ≥50 years, with no significant gender difference. Colon cancer was more common, and most tumors were moderate or well differentiated at stages II-III. The GA genotype of GSTP1 rs1695 was significantly associated with increased CRC risk (p = 0.013), especially in those aged ≥50 years (p = 0.003). The combined AA + AG genotypes were also associated with increased risk (p = 0.016). Among females, the G allele showed higher CRC susceptibility, especially in older age (p = 0.0001). The meta-analysis of 30 studies (21,376 individuals) showed no overall association between rs1695 and CRC risk, but Iranian subgroup data indicated a modest association in AG vs. GG and AA+AG vs. GG models, which lost significance after Bonferroni correction. No publication bias was detected.
conclusionThe Iranian cohort showed an age- and gender-specific association between GSTP1 rs1695 and CRC risk. However, the meta-analysis did not support a consistent link, suggesting possible population-specific effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.